


Expected submission timeline⁽¹⁾

Pipeline charts as communicated at Q4 and Full Year 2019 Results Meeting dated February 6, 2020



- Immuno-inflammation
- MS & Neuro
- Oncology
- Diabetes
- Rare Diseases
- Cardiovascular & metabolism
- Rare Blood Disorders
- Vaccines

(1) Excluding Phase 1 (without POC)
 (2) Projects within a specified year are not arranged by submission timing
 (3) Developed in collaboration with Regeneron
 (4) Acid Sphingomyelinase Deficiency
 (5) Developed in collaboration with Sobi
 (6) Autosomal Dominant Polycystic Kidney Disease

(7) Developed in collaboration with Principia
 (8) Developed in collaboration with AstraZeneca
 (9) Parkinson's Disease with an associated GBA mutation
 (10) cemiplimab 1L NSCLC submission is expected in 2020-2021
 (11) Developed in collaboration with Kitasato and Daiichi Sankyo (KDSV)
 (**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products